The CHADS-VASc score is a predictor of no-reflow in patients with non-ST-segment elevation myocardial infarction

Coron Artery Dis. 2020 Jan;31(1):7-12. doi: 10.1097/MCA.0000000000000781.

Abstract

This study was performed to evaluate the relationship between the CHA2DS2-VASc score and no-reflow (NR) phenomena in patients with non-ST-segment elevation myocardial infarction (NSTEMI). A total number of 428 consecutive patients with NSTEMI were assessed for this study. Patients were divided into 2 groups, those with NR, NR(+) (n=84), and those without NR, NR(-) (n=307), according to their post-PCI, no-reflow status. The CHA2DS2-VASc score was significantly higher in the NR(+) group compared to the NR(-) (3.48 ± 1.19 vs 1.81 ± 0.82, P < 0.001). After a multivariate regression analysis, a higher CHA2DS2-VASc score (OR: 6.52, 95% CI: 3.51-12.14, P < 0.001), hs-Troponin (OR: 1.077, 95% CI: 1.056-1.099, P< 0.001) and TTG (OR: 1.563, 95% CI: 1.134-2.154, P=0.006) were independent predictors of NR. CHA2DS2-VASc score is associated with higher risk of no-reflow in patients with NSTEMI undergoing PCI.

MeSH terms

  • C-Reactive Protein / metabolism
  • Coronary Angiography
  • Creatinine / metabolism
  • Diabetes Mellitus / epidemiology
  • Female
  • Heart Failure / epidemiology
  • Humans
  • Hypertension / epidemiology
  • Ischemic Attack, Transient / epidemiology
  • Male
  • Middle Aged
  • Multivariate Analysis
  • No-Reflow Phenomenon / epidemiology*
  • Non-ST Elevated Myocardial Infarction / diagnostic imaging
  • Non-ST Elevated Myocardial Infarction / metabolism
  • Non-ST Elevated Myocardial Infarction / physiopathology
  • Non-ST Elevated Myocardial Infarction / surgery*
  • Percutaneous Coronary Intervention*
  • Prospective Studies
  • Risk Factors
  • Stents
  • Stroke / epidemiology
  • Thrombosis / diagnostic imaging
  • Thrombosis / physiopathology
  • Thrombosis / surgery*
  • Troponin / blood

Substances

  • Troponin
  • C-Reactive Protein
  • Creatinine